Showing 1 - 10 of 14
The relationship between costs and health benefits of branded pharmaceuticals remains controversial. This paper examines the incremental costs incurred for incremental health benefits gained from the largest available sample of cost-effectiveness studies of branded drugs in the USA, the...
Persistent link: https://www.econbiz.de/10013366987
In his Labor Day address, President Biden stated that the U.S. "has the highest drug prices in the world, and there is no reason for it." For new branded drugs, the first part of that statement is supported by a recent RAND Report (Mulcahy et. al. 2021) which found U.S. average prices are 2.3...
Persistent link: https://www.econbiz.de/10014287373
Persistent link: https://www.econbiz.de/10000675333
Persistent link: https://www.econbiz.de/10011405917
Persistent link: https://www.econbiz.de/10001612430
Persistent link: https://www.econbiz.de/10013433326
Persistent link: https://www.econbiz.de/10003543678
Persistent link: https://www.econbiz.de/10009487486
Persistent link: https://www.econbiz.de/10011498813
Persistent link: https://www.econbiz.de/10011405914